Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 4/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640167 | 0.81 | BMPR1B (0.34) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL25807021 | 0.80 | KDM4E (0.31) | — | |
| SCHEMBL24759404 | 0.76 | ALDH1A1 (0.33) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21459701 | 0.76 | BCL2 (0.36) | SMN1; SMN2PTGS2 | |
| SCHEMBL25605963 | 0.73 | BMPR1B (0.31) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL12172358 | 0.72 | MAP2K2 (0.39) | BRD4DAO | |
| SCHEMBL21459327 | 0.71 | MAP2K2 (0.35) | ALDH1A1 | |
| SCHEMBL15468852 | 0.71 | ADORA2A (0.33) | BRD4ADORA2AADORA1 | |
| SCHEMBL25807020 | 0.69 | ADRA2A (0.43) | ACVRL1ACVR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21475958 | 0.69 | CHEK1 (0.37) | ACVR1BRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | BMPR1B 1808/4885BMPR1A 1773/4885ACVRL1 2433/4885 |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | BMPR1B 1651/4885BMPR1A 1825/4885ACVRL1 1954/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | BMPR1B 1808/4885BMPR1A 1773/4885ACVRL1 2433/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | BMPR1B 1979/4885BMPR1A 2432/4885ACVRL1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.